Please login to the form below

Not currently logged in
Email:
Password:

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Tecentriq is currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the ... SCLC is less common than NSCLC but tends to be more aggressive,

Latest news

More from news
Approximately 6 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  .

  • Deal Watch April 2016 Deal Watch April 2016

    Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.

  • Deal Watch November 2015 Deal Watch November 2015

    July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...